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Background
The periodic fever, aphthous stomatitis, pharyngitis and
cervical adenitis (PFAPA) syndrome belongs to the rare
nonhereditary autoinflammatory diseases and normally
onsetting in childhood, but despite of tonsillectomy persist-
ing or newly occurring in adulthood. The exact pathogen-
esis is not clear, but to our understanding it is an acquired
autoinflammatory disease due to an unregulated production
of cytokines. The common treatment varies from NSAIDS,
colchicine, corticosteroids up to blocking IL1- receptor.
Objectives
The anti-IL1ß-monoclonal antibody canakinumab has
been introduced as a specific therapy in patient with cryo-
pyrin-associated periodic syndromes (CAPS). There is
only very few data about the effect of canakinumab in
patients with PFAPA syndrome in off label use.
Methods
Here we report about two unrelated female patients, 20
and 49 years old, with PFAPA syndrome diagnosed in
2014 respectively 2012 with no treatment response to
NSAIDS, colchicine, corticosteroids and severe side effects
or no reduction of disease activity under the therapy with
anakinra. Therefore, we initiated a subcutaneous therapy
with canakinumab using standard dosage of 150 mg every
eight weeks while monitoring clinical response and inflam-
mation markers C-reactive protein (CRP) plus serumamy-
loid A (SAA).
Results
Immediately after first injection both patients showed a
good response to canakinumab with reduced activity of
inflammation markers, reduction of the typical clinical
symptoms and ultimately with an improved quality of
life. Even over the period of 6 months respectively two
years we have seen a lasting effect of canakinumab with
reduction of disease activity.
Conclusions
In our experience, treatment with the anti-IL1ß-monoclonal
antibody canakinumab might be an effective, safe and feasi-
ble treatment showing no severe side effects and should be
considered as a new therapeutic option in off label use in
patients with PFAPA syndrome.
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